Milestone Pharmaceuticals Inc（MIST）の株式分析MISTMilestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Milestone Pharmaceuticals Inc is a good buy right now due to its recent positive developments, including a pivotal Phase 3 trial initiation for etripamil, which could significantly enhance its market position. The stock is currently priced at $1.16, and analysts have set a price target of $3, indicating a potential upside of over 150%. Additionally, the company reported a significant increase in prescriptions for its product, with Q2 2026 revenue reaching $559,000, a notable improvement from previous quarters. However, the main risk is the ongoing net losses, with a reported loss of $28.6 million in Q2 2026, which could impact future performance if not addressed.